http://www.acc.org/Feed?clinicalTopicID=a6997643-d7bf-4b8d-b578-d65877161636 Clinical Topic Feed: Novel Agents en /Latest-in-Cardiology/Journal-Scans/2026/09/10/19/19/JACC-CardioOncology-Primer As the use of antibody-drug conjugates (ADCs) continue to expand in breast cancer, understanding the potential cardiovascular risks is increasingly important, particularly in curative settings. 1789572000000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-amundsen-esc-2026 First-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction in patients with acute MI undergoing PCI, with more than 80% reaching the guideline recommended target of LDL-C less than 55 mg/dL at one year, said researchers presenting findings from the AMUNDSEN trial at ESC Congress 2026. However, no clinical benefit was detected during the first year of follow-up. 1787992740000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-245am-tranquility-esc-2026 Pacibekitug, a novel, long-acting monoclonal antibody that targets interleukin-6, produced sustained reductions in inflammatory markers in patients with chronic kidney disease (CKD) and at high inflammatory risk, with no clear dose-related safety signals identified, based on findings from the TRANQUILITY study presented at ESC Congress 2026. 1787992740000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-215am-staree-esc-2026 Among community-dwelling older adults, treatment with atorvastatin demonstrated a 30% relative reduction in major cardiovascular events over roughly six years compared with placebo but did not result in longer disability-free survival, based on findings from the STAREE trial presented at ESC Congress 2026 and simultaneously published in NEJM. 1787991840000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/17/15/29/A-Rare-Pattern-of-Harm Statin therapy remains a cornerstone in the prevention of cardiovascular (CV) morbidity and mortality. Although statin-associated muscle symptoms are relatively common and often self-limited, severe statin-associated immune-mediated necrotizing myopathy (IMNM) has emerged as a rare but important clinical entity. 1786989360000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/16/16/01/eagles-eye-view-17jun2026 In this week’s View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men. 1781701440000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/08/17/44/SOGALDI-PEF Patients with low plasma renin levels had a more pronounced blood pressure (BP) reduction with spironolactone/dapagliflozin vs. dapagliflozin alone, in addition to seeing a more favorable impact on cardiovascular structure and function, while aldosterone levels exhibited no predictive value in treatment response... 1781118900000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/03/20/12/New-Research Three new studies published in Circulation highlight advances in lipid-lowering therapy, with early-stage data supporting a first-in-class oral PCSK9 inhibitor and two separate analyses showing that evolocumab reduces major cardiovascular events across a range of high-risk patients, including those with elevated Lp(a) and those with prior PCI but no history of MI. 1780519500000 Articles and Stories /Latest-in-Cardiology/Articles/2026/05/27/15/57/eagles-eye-view-27may2026 In this week’s View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment. 1779898740000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/05/18/18/10/New-Studies-Add-to-Evidence Treatment of patients following ischemic stroke was the focus of three separate studies published in JAMA, two of which involved use of intravenous tenecteplase and the other involving thrombectomy plus intra-arterial alteplase. 1779219300000 Articles and Stories